EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Precision medicine in rare diseases: What is next?

Bianca Tesi iD, Catherine Boileau, Kym M Boycott, Guillaume Canaud, Mark Caulfield, Daniela Choukair, Sue Hill, Malte Spielmann, Anna Wedell, Valtteri Wirta, Ann Nordgren, Anna Lindstrand

Journal of Internal Medicine · 2023-10 · 294 (4) · 397-412

DOI: 10.1111/joim.13655 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Internal Medicine, 2023-06. Verfasst von Bianca Tesi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery and Centre of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Precision Medicine, Rare Diseases. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molecular diagnostics is a cornerstone of modern precision medicine, broadly understood as tailoring an individual's treatment, follow‐up, and care based on molecular data. In rare diseases (RDs), molecular diagnoses reveal valuable information about the cause of symptoms, disease progression, familial risk, and in certain cases, unlock access to targeted therapies. Due to decreasing DNA sequencing costs, genome sequencing (GS) is emerging as the primary method for precision diagnostics in RDs. Several ongoing European initiatives for precision medicine have chosen GS as their method of choice. Recent research supports the role for GS as first‐line genetic investigation in individuals with suspected RD, due to its improved diagnostic yield compared to other methods. Moreover, GS can detect a broad range of genetic aberrations including those in noncoding regions, producing comprehensive data that can be periodically reanalyzed for years to come when further evidence emerges. Indeed, targeted drug development and repurposing of medicines can be accelerated as more individuals with RDs receive a molecular diagnosis. Multidisciplinary teams in which clinical specialists collaborate with geneticists, genomics education of professionals and the public, and dialogue with patient advocacy groups are essential elements for the integration of precision medicine into clinical practice worldwide. It is also paramount that large research projects share genetic data and leverage novel technologies to fully diagnose individuals with RDs. In conclusion, GS increases diagnostic yields and is a crucial step toward precision medicine for RDs. Its clinical implementation will enable better patient management, unlock targeted therapies, and guide the development of innovative treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineRare DiseasesHumansGenomicsSequence Analysis, DNADisease Progression

Stichwörter der Autor:innen

data sharinggene therapygenome sequencingmolecular diagnosisprecision medicinerare diseases

Autor:innen und Institutionen

  • Department of Molecular Medicine and Surgery and Centre of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
  • Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Département de Génétique, APHP, Hôpital Bichat-Claude Bernard, Université Paris Cité, Paris, France.
  • Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
  • INSERM U1151, Unité de médecine translationnelle et thérapies ciblées, Hôpital Necker-Enfants Malades, Université Paris Cité, AP-HP, Paris, France.

ORCID-Profile: Bianca Tesi

Zitieren

APA

Tesi, B., Boileau, C., Boycott, K. M., Canaud, G., Caulfield, M., Choukair, D., Hill, S., Spielmann, M., Wedell, A., Wirta, V., Nordgren, A., & Lindstrand, A. (2023). Precision medicine in rare diseases: What is next?. Journal of Internal Medicine, 294(4), 397-412. https://doi.org/10.1111/joim.13655

Vancouver

Tesi B, Boileau C, Boycott KM, Canaud G, Caulfield M, Choukair D, et al. Precision medicine in rare diseases: What is next?. Journal of Internal Medicine. 2023;294(4):397-412. doi:10.1111/joim.13655

BibTeX
@article{Tesi2023,
  author = {Tesi, Bianca and Boileau, Catherine and Boycott, Kym M and Canaud, Guillaume and Caulfield, Mark and Choukair, Daniela and Hill, Sue and Spielmann, Malte and Wedell, Anna and Wirta, Valtteri and Nordgren, Ann and Lindstrand, Anna},
  title = {Precision medicine in rare diseases: What is next?},
  journal = {Journal of Internal Medicine},
  year = {2023},
  volume = {294},
  number = {4},
  pages = {397--412},
  doi = {10.1111/joim.13655}
}
Kostenlos starten →